Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Anxiolytics vs inactive control Cardiovascular mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Cardiovascular mortality · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Cardiovascular mortality · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Serious adverse events · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Quality of sleep · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Quality of life · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control All‐cause mortality · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Change in class of malocclusion · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in DMFT index · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in severity of periodontitis (measured by reduction in clinical attachment loss) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: oral infections (measured by reduction in or resolution of lesions such as periapical cysts, abscesses, or space infections) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: systemic infections (measured by number of episodes after treatment for dental complications under antibiotic prophylaxis) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Any other adverse effects related to treatment · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Time to recurrence ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Quality of life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Time to response ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Overall response rate (ORR), · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Overall survival (OS) · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Adverse events · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Time to recurrence — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Quality of life — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Quality of life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Infusion reactions · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Need for respiratory support · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo QoL · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Treatment‐related adverse events · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Infusion reactions · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Need for respiratory support · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo QoL · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
VAL‐1221 vs alglucosidase alfa Change in FVC (% predicted) · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |